Current Edition

Optimising Early Clinical Development Strategies in Oncology

According to the largest analysis of almost 7,500 clinical and regulatory phase transitions, the likelihood of an oncology drug progressing from Phase I clinical testing is 5%, the lowest of the 14 major disease areas analysed. Of the oncology drugs that do progress, twice as many are for haematological malignancies than for solid tumours. Dr. Steve McConchie at Aptus Clinical shows more about the strategies in the clinical development in Oncology.